摘要
目的:观察重组人脑利钠肽(rhBNP)治疗慢性充血性心力衰竭的临床治疗效果及安全性。方法:选取147例慢性充血性心衰患者,随机分为rhBNP治疗组(n=78)和硝普钠(SN)治疗组(n=69),观察治疗后2周两组的临床治疗效果,并检测治疗前后的心、肾功能及血清BNP水平的变化。结果:治疗后2周,rhBNP治疗组显效率(80.77%)及总有效率(94.87%)均高于SN治疗组(分别65.22%和86.96%;P<0.05),差异有统计学意义;rhBNP组的左心室射血分数(LVEF)与治疗前相比显著升高(P<0.05),与SN组相比有显著性差异(P<0.05);而rhBNP组血清BNP水平较治疗前显著降低(P<0.05),且较SN组比有显著性降低(P<0.05)。结论:rhBNP可以安全、有效地用于慢性充血性心衰患者的治疗,疗效优于硝普钠。
Objective： To investigate the clinical efficacy and safety of recombinant human brain natriuretic peptide（rhBNP） on the treatment of congestive heart failure.Methods： 147 patients with congestive heart failure were randomly divided into rhBNP group（n=78） and Sodium Nitroprusside（SN） group（n=69）,the clinical curative effects were observed,the plasma level of BNP and function of heart and kidney were measured in these patients before and 2 weeks after study.Results： After 2-weeks treatment,the excellent rate（59.62 %） and total effective rate（90.38 %） in rhBNP group were significantly higher than those in SN group（39.13 % and 73.91 %,respectively;P0.05）;the LVEF level in rhBNP group was obviously increased in comparison with those in pre-treatment（P0.05）,and significant difference was also find between the two groups;the plasma level of BNP in rhBNP group were significantly lower（P0.05） than those in pre-treatment and SN group.Conclusion： rhBNP is an effective and safe drug for the treatment of congestive heart failure,and it is more effectual and secure than nitroprusside.
出处
《现代生物医学进展》
CAS
2013年第16期3088-3090,3059,共4页
Progress in Modern Biomedicine
关键词
充血性心衰
重组人脑利钠肽
硝普钠
临床疗效
安全性
Congestive heart failure（CHF）
rhBNP（Recombinant Human Brain Natriuretic Peptide）
Sodium Nitroprusside（SN）
Clinical efficacy
Safety
